[1. B. M. Reid, J. B. Permuth and T. A. Sellers, Epidemiology of ovarian cancer: a review, Cancer Biol. Med. 14 (2017) 9–32; https://doi.org/10.20892/j.issn.2095-3941.2016.008410.20892/j.issn.2095-3941.2016.0084536518728443200]Search in Google Scholar
[2. J. Permuth-Wey and T. A. Sellers, 20. Epidemiology of Ovarian Cancer, in Cancer Epidemiology: Modifiable Factors (Ed. M. Verma)/Series: Methods of Molecular Biology472 (2009) 413–437, Springer, New York 2009; https://doi.org/10.1007/978-1-60327-492-0_2010.1007/978-1-60327-492-0_2019107446]Search in Google Scholar
[3. J. Ledermann, F. Raja, C. Fotopoulou, A. Gonzalez-Martin, N. Colombo and C. Sessa (ESMO guidelines working group), Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up, Ann. Oncol.24 (Suppl. 6) (2013) vi24-vi32. https://doi.org/10.1093/annonc/mdt33310.1093/annonc/mdt33324078660]Search in Google Scholar
[4. F. Raja, N. Chopra and J. Ledermann, Optimal first-line treatment in ovarian cancer, Ann. Oncol. 23 (Suppl. 10) (2012) x118-x127; https://doi.org/10.1093/annonc/mds31510.1093/annonc/mds31522987945]Search in Google Scholar
[5. M. Cristea, E. Han, L. Salmon and R. J. Morgan, Review: Practical considerations in ovarian cancer chemotherapy, Ther. Adv. Med. Oncol. 2 (2010) 175–187; https://doi.org/10.1177/175883401036133310.1177/1758834010361333312601621789133]Search in Google Scholar
[6. M. Kyrgiou, G. Salanti, N. Pavlidis, E. Paraskevaidi and J. P. Ioannidis, Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments, J. Natl. Cancer Inst.98 (2006) 1655–1663; https://doi.org/10.1093/jnci/djj44310.1093/jnci/djj44317105988]Search in Google Scholar
[7. M. A. Bookman (Ed.), GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma, J. Clin. Oncol. 24 (Suppl.) (2006) 5002–5002 (ASCO Annual Meeting Proceedings 2006); https://doi.org/10.1200/jco.2006.24.18_suppl.500210.1200/jco.2006.24.18_suppl.5002]Search in Google Scholar
[8. J. A. Ledermann and R. S. Kristeleit, Optimal treatment for relapsing ovarian cancer, Ann. Oncol. 21 (Suppl. 7) (2010) vii218-222; https://doi.org/10.1093/annonc/mdq37710.1093/annonc/mdq37720943618]Search in Google Scholar
[9. D. S. Dizon, M. L. Hensley, E. A. Poynor, P. Sabbatini, C. Aghajanian, A. E. Hummer. D. R. Venkatraman and R. Spriggs, Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer, J. Clin. Oncol. 20 (2002) 1238–1247; https://doi.org/10.1200/JCO.2002.20.5.123810.1200/JCO.2002.20.5.123811870166]Search in Google Scholar
[10. M. U. Rashid, A. Zaidi, D. Torres, F. Sultan, A. Benner, B. Naqvi, A. R. Shakoori, A. Seidel-Renkert, H. Farooq, S. Narod, A. Amin and U. Hamann, Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients, Int. J. Cancer119 (2006) 2832–2839; https://doi.org/10.1002/ijc.2226910.1002/ijc.2226916998791]Search in Google Scholar
[11. M. A. Moore, Y. Ariyaratne, F. Badar, Y. Bhurgri, K. Datta, A. Mathew, P. Gangadharan, A. Nandakumar, K. K. Pradhananga, M. H. Talukder, B. B. Yeole and T. Sobue, Cancer epidemiology in South Asia - past, present and future, Asian Pac. J. Cancer Prev. 11 (Suppl. 2) (2010) 49–66.]Search in Google Scholar
[12. Y. Bhurgri, Karachi cancer registry data - implications for the National Cancer Control Program of Pakistan, Asian Pac. J. Cancer Prev.5 (2004) 77–82.]Search in Google Scholar
[13. Ovarian cancer second most common type in Pakistan, The Daily News 2016, https://www.the-news.com.pk/print/105779-Ovarian-cancer-second-most-common-type-inPakistan; last access date July 15, 2018.]Search in Google Scholar
[14. P. Cheema and R. Burkes, Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer, Curr. Oncol.20 (2013) e150; https://doi.org/10.3747/co.20.122610.3747/co.20.1226361586623559882]Search in Google Scholar
[15. E. Eisenhauer, P. Therasse, J. Bogaerts, L. H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe and J. Verweij, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur. J. Cancer45 (2009) 228–247; https://doi.org/10.1016/j.ejca.2008.10.02610.1016/j.ejca.2008.10.02619097774]Search in Google Scholar
[16. S. Zhang, F. Liang and I. Tannock, Use and misuse of common terminology criteria for adverse events in cancer clinical trials, BMC Cancer16 (2016) Article ID 392 (6 pages); https://doi.org/10.1186/s12885-016-2408-910.1186/s12885-016-2408-9493272627377548]Search in Google Scholar
[17. C. Aghajanian, S. V. Blank, B. A. Goff, P. L. Judson, M. G. Teneriello, A. Husain, M. A. Sovak, J. Yi and L. R. Nycum, OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer, J. Clin. Oncol.30 (2012) 2039–2045; https://doi.org/10.1200/JCO.2012.42.050510.1200/JCO.2012.42.0505364632122529265]Search in Google Scholar
[18. M. Kyrgiou, G. Salanti, N. Pavlidis, E. Paraskevaidis and J. P. Ioannidis, Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments, J. Natl. Cancer Inst.98 (2006) 1655–1663; https://doi.org/10.1093/jnci/djj44310.1093/jnci/djj44317105988]Search in Google Scholar
[19. S. Pignata, G. Scambia, G. Ferrandina, A. Savarese, R. Sorio, E. Breda, V. Gebbia, P. Musso, L. Frigerio, P. Del Medico, A. V. Lombardi, A. Febbraro, P. Scollo, A. Ferro, S. Tamberi, A. Brandes, A. Ravaioli, M. R. Valerio, E. Aitini, D. Natale, L. Scaltriti, S. Greggi, C. Pisano, D. Lorusso, V. Salutari, F. Legge, M. Di Maio, A. Morabito, C. Gallo and F. Perrone, Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial, J. Clin. Oncol.29 (2011) 3628–3635; https://doi.org/10.1200/JCO.2010.33.856610.1200/JCO.2010.33.856621844495]Search in Google Scholar
[20. R. S. Suidan, C. M. St Clair, S. J. Lee, J. N. Barlin, K. C. Long Roche, E. J. Tanner, Y. Sonoda, R. R. Barakat, O. Zivanovic and D. S. Chi, A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer, Gynecol. Oncol. 134 (2014) 468–472; https://doi.org/10.1016/j.ygyno.2014.07.09010.1016/j.ygyno.2014.07.09025042672]Search in Google Scholar
[21. M. J. Piccart, K. Bertelsen, K. James, J. Cassidy, C. Mangioni, E. Simonsen, G. Stuart, S. Kaye, I. Vergote, R. B. R. Grimshaw, R. J. Atkinson, K. D. Swenerton, C. Trope, M. Nardi, J. Kaern, S. Tumolo, P. Timmers, J. Roy, F. Lhoas, B. Lindvall, M. Bacon, A. Birt, J. E. Andersen, B. Zee, J. Paul, B. Baron and S. Pecorelli, Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin–cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results, J. Natl. Cancer Inst.92 (2000) 699–708; https://doi.org/10.1093/jnci/92.9.69910.1093/jnci/92.9.69910793106]Search in Google Scholar
[22. A. du Bois, H. J. Lück, W. Meier, H. P. Adams, V. Möbus, S. Costa, T. Bauknecht, B. Richter, M. Warm, W. Schröder, S. Olbricht, U. Nitz, C. Jackisch, G. Emons, U. Wagner, W. Kuhn and J. Pfisterer, A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer, J. Natl. Cancer Inst. 95 (2003) 1320–1329; doi 10.1093/jnci/djg03610.1093/jnci/djg03612953086]Search in Google Scholar
[23. R. F. Ozols, B. N. Bundy, B. E. Greer, J. M. Fowler, D. Clarke-Pearson, R. A. Burger, R. S. Mannel, K. DeGeest, E. M. Hartenbach and R. Baergen, Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study, J. Clin. Oncol.21 (2003) 3194–3200; https://doi.org/10.1200/jco.2003.02.15310.1200/JCO.2003.02.15312860964]Search in Google Scholar
[24. M. Fung-Kee-Fung, T. Oliver, L. Elit, A. Oza, H. W. Hirte and P. Bryson, Optimal chemotherapy treatment for women with recurrent ovarian cancer, Curr. Oncol.14 (2007) 195–208.10.3747/co.2007.148]Search in Google Scholar
[25. Y. Wang, J. Herrstedt, H. Havsteen, R. DePoint Christensen, M. R. Mirza, B. Lund, J. Maenpaa and G. Kristensen, A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer, BMC Cancer14 (2014) Article ID 937 (7 pages); https://doi.org/10.1186/1471-2407-14-93710.1186/1471-2407-14-937]Search in Google Scholar
[26. L. A. Holmberg, P. Paley and B. Goff, Docetaxel and carboplatin as salvage therapy for first-relapsed, platinum-sensitive, stage III/IV advanced ovarian cancer, Clin. Ovar. Other Gynecol. Cancer7 (2014) 13–17; https://doi.org/10.1016/j.cogc.2014.12.00510.1016/j.cogc.2014.12.005]Search in Google Scholar
[27. J. M. Gibson, S. Alzghari, C. Ahn, H. Trantham and N. M. La-Beck, The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials, Oncologist18 (2013) 1022–1031; https://doi.org/10.1634/theoncologist.2013-012610.1634/theoncologist.2013-0126]Search in Google Scholar
[28. M. Parmar, J. Ledermann, N. Colombo, A. du Bois, J. F. Delaloye, G. B. Kristensen, S. Wheeler, A. M. Swart, W. Qian, V. Torri, I. Floriani, G. Jayson and A. Lamont, C. Tropé, Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial, Lancet361 (2003) 2099–2106; https://doi.org/10.1016/S0140-6736(03)13718-X10.1016/S0140-6736(03)13718-X]Search in Google Scholar
[29. J. Pfisterer, M. Plante, I. Vergote, A. du Bois, H. Hirte, A. J. Lacave, U. Wagner, A. Stähle, G. Stuart, R. Kimmig, S. Olbricht, T. Le, J. Emerich, W. Kuhn, J. Bentley, C. Jackisch, H. J. Lück, J. Rochon, A. H. Zimmermann and E. Eisenhauer, Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG, J. Clin. Oncol.24 (2006) 4699–4707; https://doi.org/10.1200/JCO.2006.06.091310.1200/JCO.2006.06.091316966687]Search in Google Scholar
[30. D. Bafaloukos, H. Linardou, G. Aravantinos, C. Papadimitriou, A. Bamias, G. Fountzilas, H. P. Kalofonos, P. Kosmidis, E. Timotheadou, T. Makatsoris, E. Samantas, E. Briasoulis, C. Christodoulou, P. Papakostas, D. Pectasides and A. M. Dimopoulos, A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study, BMC Med.8 (2010) Article ID 3 (12 pages); https://doi.org/10.1186/1741-7015-8-310.1186/1741-7015-8-3282365320055981]Search in Google Scholar
[31. C. J. Dunton, Management of treatment-related toxicity in advanced ovarian cancer, Oncologist7 (Suppl. 5) (2002) 11–19.10.1634/theoncologist.7-suppl_5-1112324629]Search in Google Scholar
[32. K. Kudoh, M. Takano, H. Kouta, R. Kikuchi, T. Kita, M. Miyamoto, A. Watanabe, M. Kato, T. Goto and Y. Kikuchi, Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers, Gynecol. Oncol.122 (2011) 233–237; https://doi.org/10.1016/j.ygyno.2011.04.04610.1016/j.ygyno.2011.04.04621601912]Search in Google Scholar